Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS.

Blood. 2018 Jun 14;131(24):2661-2669. doi: 10.1182/blood-2017-12-818948. Epub 2018 May 3.

PMID:
29724899
2.

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Sivaraj D, Bacon W, Long GD, Rizzieri DA, Horwitz ME, Sullivan KM, Kang Y, Li Z, Chao NJ, Gasparetto C.

Bone Marrow Transplant. 2018 Jan;53(1):34-38. doi: 10.1038/bmt.2017.208. Epub 2017 Oct 30.

PMID:
29084203
3.

HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group.

Guo M, Chao NJ, Li JY, Rizzieri DA, Sun QY, Mohrbacher A, Krakow EF, Sun WJ, Shen XL, Zhan XR, Wu DP, Liu L, Wang J, Zhou M, Yang LH, Bao YY, Dong Z, Cai B, Hu KX, Yu CL, Qiao JH, Zuo HL, Huang YJ, Sung AD, Qiao JX, Liu ZQ, Liu TQ, Yao B, Zhao HX, Qian SX, Liu WW, Forés R, Duarte RF, Ai HS; Microtransplantation Interest Group.

JAMA Oncol. 2018 Jan 1;4(1):54-62. doi: 10.1001/jamaoncol.2017.2656.

PMID:
28910431
4.

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.

Stephens SJ, Thomas S, Rizzieri DA, Horwitz ME, Chao NJ, Engemann AM, Lassiter M, Kelsey CR.

Adv Radiat Oncol. 2016 Jul 15;1(4):272-280. doi: 10.1016/j.adro.2016.07.001. eCollection 2016 Oct-Dec.

5.

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Anand S, Thomas S, Corbet K, Gasparetto C, Long GD, Lopez R, Morris AK, Rizzieri DA, Sullivan KM, Sung AD, Sarantopoulos S, Chao NJ, Horwitz ME.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1949-1954. doi: 10.1016/j.bbmt.2017.06.027. Epub 2017 Jul 17.

6.

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.

Boss MK, Dewhirst MW, Sampaio RS, Bennett A, Tovmasyan A, Berman KG, Beaven AW, Rizzieri DA, Batinic-Haberle I, Hauck ML, Spasojevic I.

Cancer Chemother Pharmacol. 2017 Aug;80(2):421-431. doi: 10.1007/s00280-017-3372-z. Epub 2017 Jul 6.

7.

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.

Anand S, Thomas S, Hyslop T, Adcock J, Corbet K, Gasparetto C, Lopez R, Long GD, Morris AK, Rizzieri DA, Sullivan KM, Sung AD, Sarantopoulos S, Chao NJ, Horwitz ME.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1151-1157. doi: 10.1016/j.bbmt.2017.04.001. Epub 2017 Apr 6.

8.

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.

Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W; Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaboration between the National Marrow Donor Program/Be the Match Registry and theMedicalCollegeofWisconsin.

Cancer. 2017 Jun 1;123(11):2035-2042. doi: 10.1002/cncr.30567. Epub 2017 Jan 24.

9.

Treatment of blastic plasmacytoid dendritic cell neoplasm.

Sullivan JM, Rizzieri DA.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):16-23. Review.

PMID:
27913457
10.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.

Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, Long GD, Horwitz ME, Lopez RD, Sullivan KM, Rizzieri DA, Chao NJ, Gasparetto C.

Biol Blood Marrow Transplant. 2017 Feb;23(2):262-268. doi: 10.1016/j.bbmt.2016.11.010. Epub 2016 Nov 14.

11.

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.

Zahid MF, Patnaik MM, Gangat N, Hashmi SK, Rizzieri DA.

Eur J Haematol. 2016 Oct;97(4):313-20. doi: 10.1111/ejh.12771. Epub 2016 May 31. Review.

PMID:
27147278
12.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W.

J Clin Oncol. 2016 Jun 1;34(16):1864-71. doi: 10.1200/JCO.2015.65.0515. Epub 2016 Apr 4.

13.

Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.

Zahid MF, Rizzieri DA.

Adv Hematol. 2016;2016:1423493. doi: 10.1155/2016/1423493. Epub 2016 Feb 2. Review.

14.

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.

Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L, Borthakur G.

Leuk Lymphoma. 2016 Aug;57(8):1800-6. doi: 10.3109/10428194.2015.1122781. Epub 2016 Jan 6.

PMID:
26735141
15.

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.

Griffin PT, Komrokji RS, De Castro CM, Rizzieri DA, Melchert M, List AF, Lancet JE.

Am J Hematol. 2015 Sep;90(9):796-9. doi: 10.1002/ajh.24087. Epub 2015 Aug 14.

16.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1746-53. doi: 10.1016/j.bbmt.2015.05.010. Epub 2015 May 15.

17.

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Rein LA, Rizzieri DA.

Ther Adv Hematol. 2014 Dec;5(6):211-20. doi: 10.1177/2040620714552615. Review.

18.

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.

Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH, Ballen KK, Wirk B, Munker R, Rizzieri DA, Chen YB, Gibson J, Akpek G, Costa LJ, Kamble RT, Aljurf MD, Hsu JW, Cairo MS, Schouten HC, Bacher U, Savani BN, Wingard JR, Lazarus HM, Laport GG, Montoto S, Maloney DG, Smith SM, Brunstein C, Saber W.

Bone Marrow Transplant. 2015 Feb;50(2):197-203. doi: 10.1038/bmt.2014.259. Epub 2014 Nov 17.

19.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.

20.

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.

Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McDonald C, Waters-Pick B, Stiff P, Wease S, Peled A, Snyder D, Cohen EG, Shoham H, Landau E, Friend E, Peleg I, Aschengrau D, Yackoubov D, Kurtzberg J, Peled T.

J Clin Invest. 2014 Jul;124(7):3121-8. doi: 10.1172/JCI74556. Epub 2014 Jun 9.

21.

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W.

Biol Blood Marrow Transplant. 2014 Jul;20(7):951-9. doi: 10.1016/j.bbmt.2014.03.014. Epub 2014 Mar 15.

22.

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION).

Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15.

23.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN.

J Clin Oncol. 2014 Feb 1;32(4):273-81. doi: 10.1200/JCO.2013.49.2454. Epub 2013 Dec 16.

24.

New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.

Rein LA, Sung AD, Rizzieri DA.

Int J Hematol Oncol. 2013 Feb;2(1). doi: 10.2217/ijh.13.4.

25.

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA.

Biol Blood Marrow Transplant. 2014 Feb;20(2):257-63. doi: 10.1016/j.bbmt.2013.11.010. Epub 2013 Nov 20.

26.

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI.

J Clin Oncol. 2013 Nov 20;31(33):4199-206. doi: 10.1200/JCO.2012.48.3685. Epub 2013 Oct 14.

27.

Providing personalized prognostic information for adult leukemia survivors.

Lee SJ, Storer B, Wang H, Lazarus HM, Waller EK, Isola LM, Klumpp TR, Umejiego JB, Savani BN, Loren AW, Cairo MS, Camitta BM, Cutler CS, George B, Jean Khoury H, Marks DI, Rizzieri DA, Copelan EA, Gupta V, Liesveld JL, Litzow MR, Miller AM, Schouten HC, Gale RP, Cahn JY, Weisdorf DJ.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1600-7. doi: 10.1016/j.bbmt.2013.08.013. Epub 2013 Sep 6.

28.

Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.

Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN.

Br J Haematol. 2013 Sep;162(5):648-56. doi: 10.1111/bjh.12451. Epub 2013 Jul 6.

29.

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2298-307. doi: 10.1073/pnas.1301838110. Epub 2013 Jun 4.

30.

Leukemic stem cells: a review.

O'Brien JA, Rizzieri DA.

Cancer Invest. 2013 May;31(4):215-20. doi: 10.3109/07357907.2012.700986. Epub 2013 Mar 8. Review.

PMID:
23473080
31.

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM.

Biol Blood Marrow Transplant. 2013 May;19(5):746-53. doi: 10.1016/j.bbmt.2013.01.024. Epub 2013 Feb 1.

32.

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Kanda J, Kaynar L, Kanda Y, Prasad VK, Parikh SH, Lan L, Shen T, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, Winkel S, McPherson J, Kurtzberg J, Chao NJ, Horwitz ME.

Bone Marrow Transplant. 2013 Jul;48(7):926-31. doi: 10.1038/bmt.2012.279. Epub 2013 Jan 21.

33.

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM.

Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31. doi: 10.1016/j.bbmt.2013.01.009. Epub 2013 Jan 17.

34.

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Kurokawa M, Ito T, Yang CS, Zhao C, Macintyre AN, Rizzieri DA, Rathmell JC, Deininger MW, Reya T, Kornbluth S.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2300-5. doi: 10.1073/pnas.1206551110. Epub 2013 Jan 16.

35.

Genetic heterogeneity of diffuse large B-cell lymphoma.

Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398-403. doi: 10.1073/pnas.1205299110. Epub 2013 Jan 4.

36.

MDS: unraveling the mystery.

Rizzieri DA.

Blood. 2012 Dec 13;120(25):4906-8. doi: 10.1182/blood-2012-09-452755.

37.

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.

Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL.

Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9. doi: 10.1016/j.bbmt.2012.11.016. Epub 2012 Nov 27.

38.

The genetic landscape of mutations in Burkitt lymphoma.

Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS.

Nat Genet. 2012 Dec;44(12):1321-5. doi: 10.1038/ng.2468. Epub 2012 Nov 11.

39.

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

Morris TA, DeCastro CM, Diehl LF, Gockerman JP, Lagoo AS, Li Z, Moore JO, Rizzieri DA, Rao AV.

Leuk Res. 2013 Jan;37(1):28-31. doi: 10.1016/j.leukres.2012.09.016. Epub 2012 Oct 7.

40.

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.

Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, Gasparetto C, Morris A, Chao NJ, Rizzieri DA.

Cancer Invest. 2012 Nov;30(9):679-82. doi: 10.3109/07357907.2012.726386. Epub 2012 Sep 28. No abstract available.

41.

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE.

Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9.

PMID:
22772060
42.

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ.

Br J Haematol. 2012 Sep;158(5):581-8. doi: 10.1111/j.1365-2141.2012.09186.x. Epub 2012 Jun 15.

43.

Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.

Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McPherson J, Hale J, Livingston JA, Broadwater G, Niedzwiecki D, Chao NJ, Horwitz ME.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1664-1676.e1. doi: 10.1016/j.bbmt.2012.06.005. Epub 2012 Jun 12.

44.

Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria.

Rizzieri DA, Walsh K.

Clin Adv Hematol Oncol. 2012 Feb;10(2):136-7. Review. No abstract available.

PMID:
22402360
45.

Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.

Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1036-1043.e1. doi: 10.1016/j.bbmt.2011.11.026. Epub 2011 Dec 7.

46.

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Chen DF, Prasad VK, Broadwater G, Reinsmoen NL, DeOliveira A, Clark A, Sullivan KM, Chute JP, Horwitz ME, Gasparetto C, Long GD, Yang Y, Chao NJ, Rizzieri DA.

Bone Marrow Transplant. 2012 Jun;47(6):817-23. doi: 10.1038/bmt.2011.181. Epub 2011 Dec 5.

47.

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, Rizzieri DA, Sullivan KM, Chao NJ.

Bone Marrow Transplant. 2012 Aug;47(8):1051-5. doi: 10.1038/bmt.2011.217. Epub 2011 Nov 14.

48.

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.

Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ.

Bone Marrow Transplant. 2012 Jun;47(6):810-6. doi: 10.1038/bmt.2011.194. Epub 2011 Oct 10.

49.

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP, Morris A, Hennig T, Li Z, Chao NJ, Rizzieri DA.

Bone Marrow Transplant. 2012 May;47(5):700-5. doi: 10.1038/bmt.2011.158. Epub 2011 Aug 1.

50.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1796-803. doi: 10.1016/j.bbmt.2011.06.005. Epub 2011 Jun 21.

Supplemental Content

Loading ...
Support Center